IP Library Granted Patent US 8,889,419
Granted Patent B2
US 8,889,419 · App. 11/859,487 · Granted Nov 18, 2014

Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains

Inventor: David A Williams (Indianapolis, IN)
Assignee: Indiana University Research & Technology Corporation
C12N5/0636A61K48/00C12N2810/80C12N15/86C12N2740/13045C12N2510/00C12N2740/13043C12N5/0647C12N2501/58C07K14/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,419
App. No.
11/859,487
Granted
Nov 18, 2014
Kind
B2
Abstract

A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.

Claims (4)

1. A method for transducing T cells with a retrovirus, comprising prestimulating T cells with a monoclonal antibody to CD3 and IL-2 and infecting the prestimulated T cells with the retrovirus in the presence of a material including a ligand which binds to the T cells and a ligand which binds to the retrovirus, so as to co-localize the retrovirus and the cells and increase the transduction efficiency of the cells, wherein said material is a polypeptide including a first amino acid sequence comprising SEQ ID NO: 2 and a second amino acid sequence comprising SEQ ID NO: 1, and wherein said infecting the prestimulated T cells is conducted in a medium in the absence of polycations except as present from the polypeptide.

2. The method of claim 1 , wherein said T cells are mammalian T cells.

3. The method of claim 2 , wherein said T cells are human T cells.

4. The method of claim 1 , wherein said infecting is conducted in a medium free from retroviral producer cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2008
From: WILLIAMS, DAVID A
To: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.
Reel/Frame 021493/0173 →
CHANGE OF NAME Recorded Sep 8, 2008
From: ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 021493/0298 →
CONFIRMATORY LICENSE Recorded May 20, 2008
From: INDIANA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020973/0254 →
Continuity (5)
Division 10705561 · Nov 11, 2003
Division 09043981
Continuation In Part 08536891 · Sep 29, 1995
Provisional Application 60024169 · Aug 19, 1996
Related Publication 20090092589A1 · Apr 9, 2009